LLY

740.33

+2.22%↑

JNJ

149.28

+0.65%↑

UNH

275.4

+3.05%↑

ABBV

180.67

+2.24%↑

NVO

63.6

-2.53%↓

LLY

740.33

+2.22%↑

JNJ

149.28

+0.65%↑

UNH

275.4

+3.05%↑

ABBV

180.67

+2.24%↑

NVO

63.6

-2.53%↓

LLY

740.33

+2.22%↑

JNJ

149.28

+0.65%↑

UNH

275.4

+3.05%↑

ABBV

180.67

+2.24%↑

NVO

63.6

-2.53%↓

LLY

740.33

+2.22%↑

JNJ

149.28

+0.65%↑

UNH

275.4

+3.05%↑

ABBV

180.67

+2.24%↑

NVO

63.6

-2.53%↓

LLY

740.33

+2.22%↑

JNJ

149.28

+0.65%↑

UNH

275.4

+3.05%↑

ABBV

180.67

+2.24%↑

NVO

63.6

-2.53%↓

Search

Vertex Pharmaceuticals Inc

Открыт

СекторЗдравоохранение

432.11 3.25

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

417.66

Макс.

433.77

Ключевые показатели

By Trading Economics

Доход

-267M

646M

Продажи

-142M

2.8B

P/E

Средняя по отрасли

30.42

56.602

Прибыль на акцию

4.06

Рентабельность продаж

23.33

Сотрудники

6,100

EBITDA

-556M

630M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+18.74% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

31 июл. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-6.9B

113B

Предыдущая цена открытия

428.86

Предыдущая цена закрытия

432.11

Новостные настроения

By Acuity

68%

32%

349 / 382 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

5 мая 2025 г., 21:00 UTC

Отчет

Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge

10 февр. 2025 г., 22:11 UTC

Отчет

Vertex Pharmaceuticals Posts Higher 4Q Revenue

31 янв. 2025 г., 00:19 UTC

Главные движущие силы рынка

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

19 дек. 2024 г., 12:25 UTC

Главные движущие силы рынка

Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial

4 нояб. 2024 г., 21:44 UTC

Отчет

Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings

6 мая 2025 г., 16:31 UTC

Отчет

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com

5 мая 2025 г., 20:03 UTC

Отчет

Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX

5 мая 2025 г., 20:01 UTC

Отчет

Vertex Pharmaceuticals 1Q Net $646.3M >VRTX

5 мая 2025 г., 20:01 UTC

Отчет

Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX

5 мая 2025 г., 20:01 UTC

Отчет

Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX

5 мая 2025 г., 20:01 UTC

Отчет

Vertex Pharmaceuticals 1Q Adj EPS $4.06 >VRTX

27 апр. 2025 г., 11:00 UTC

Главные новости

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

11 апр. 2025 г., 09:30 UTC

Главные новости

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

28 февр. 2025 г., 12:00 UTC

Главные новости

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 февр. 2025 г., 21:12 UTC

Отчет

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

11 февр. 2025 г., 14:21 UTC

Отчет

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

10 февр. 2025 г., 21:12 UTC

Отчет

Vertex Pharmaceuticals: Duncan McKechnie, Current Head of N Amer Comml, to Assume Role of Chief Comml Officer

10 февр. 2025 г., 21:12 UTC

Отчет

Vertex Pharmaceuticals CFO Charlie Wagner to Assume Additional Role of COO

10 февр. 2025 г., 21:11 UTC

Отчет

Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1

10 февр. 2025 г., 21:04 UTC

Отчет

Vertex Pharmaceuticals Sees Combined Non-GAAP R&D, AIPR&D and SG&A Expenses $4.9B to $5.0 B >VRTX

10 февр. 2025 г., 21:04 UTC

Отчет

Vertex Pharmaceuticals Sees Combined GAAP R&D, AIPR&D and SG&A Expenses $5.55B to $5.7 B >VRTX

10 февр. 2025 г., 21:02 UTC

Отчет

Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX

10 февр. 2025 г., 21:01 UTC

Отчет

Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX

10 февр. 2025 г., 21:01 UTC

Отчет

Vertex Pharmaceuticals 4Q Net $913M >VRTX

10 февр. 2025 г., 21:01 UTC

Отчет

Vertex Pharmaceuticals 4Q Adj EPS $3.98 >VRTX

10 февр. 2025 г., 21:01 UTC

Отчет

Vertex Pharmaceuticals 4Q EPS $3.50 >VRTX

31 янв. 2025 г., 09:59 UTC

Популярные акции

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

4 нояб. 2024 г., 22:21 UTC

Отчет

Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD

4 нояб. 2024 г., 21:25 UTC

Отчет

Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD

4 нояб. 2024 г., 21:03 UTC

Отчет

Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B >VRTX

Сравнение c конкурентами

Изменение цены

Vertex Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

18.74% рост

Прогноз на 12 месяцев

Средняя 512.95 USD  18.74%

Максимум 621 USD

Минимум 423 USD

Основано на мнении 26 аналитиков Wall Street, спрогнозировавших целевые цены для Vertex Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

26 ratings

14

Покупка

12

Удержание

0

Продажа

Техническая оценка

By Trading Central

428.545 / 498.65Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Weak Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

349 / 382Рейтинг в Здравоохранение

Новостные настроения

Свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.